Bristol-Myers Squibb Future Growth

Future criteria checks 4/6

Bristol-Myers Squibb's revenue is forecast to decline at 1.6% per annum while its annual earnings are expected to grow at 43.1% per year. EPS is expected to grow by 44.8% per annum. Return on equity is forecast to be 73.1% in 3 years.

Key information

43.1%

Earnings growth rate

44.8%

EPS growth rate

Pharmaceuticals earnings growth	20.9%
Revenue growth rate	-1.6%
Future return on equity	73.1%
Analyst coverage	Good
Last updated	02 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

XTRA:BRM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	44,090	10,087	13,006	13,981	20
12/31/2025	46,166	10,245	13,981	14,396	24
12/31/2024	46,021	-5,503	14,210	6,218	24
3/31/2024	45,534	-6,148	12,509	13,724	N/A
12/31/2023	45,006	8,025	12,651	13,860	N/A
9/30/2023	44,935	8,285	11,468	12,914	N/A
6/30/2023	45,187	7,963	10,499	11,850	N/A
3/31/2023	45,848	7,311	10,860	12,224	N/A
12/31/2022	46,159	6,327	11,948	13,066	N/A
9/30/2022	46,738	6,677	12,946	13,817	N/A
6/30/2022	47,144	6,617	14,502	15,396	N/A
3/31/2022	46,960	6,251	15,347	16,195	N/A
12/31/2021	46,385	6,994	15,234	16,207	N/A
9/30/2021	45,468	-5,405	14,569	15,505	N/A
6/30/2021	44,384	-5,079	11,687	12,506	N/A
3/31/2021	42,810	-6,219	13,215	13,939	N/A
12/31/2020	42,518	-9,015	13,299	14,052	N/A
9/30/2020	39,395	-44	12,157	12,878	N/A
6/30/2020	34,862	-563	12,409	13,167	N/A
3/31/2020	31,006	954	9,939	10,757	N/A
12/31/2019	26,145	3,439	7,374	8,210	N/A
9/30/2019	24,173	5,655	7,583	8,458	N/A
6/30/2019	23,857	6,203	6,272	7,181	N/A
3/31/2019	23,288	5,144	5,239	6,155	N/A
12/31/2018	22,561	4,920	6,115	7,066	N/A
9/30/2018	22,037	1,432	3,713	4,628	N/A
6/30/2018	21,600	376	4,109	5,062	N/A
3/31/2018	21,040	919	4,586	5,589	N/A
12/31/2017	20,776	1,007	N/A	5,275	N/A
9/30/2017	20,570	4,229	N/A	5,601	N/A
6/30/2017	20,238	4,586	N/A	5,292	N/A
3/31/2017	19,965	4,836	N/A	4,147	N/A
12/31/2016	19,427	4,457	N/A	3,058	N/A
9/30/2016	18,471	3,366	N/A	2,226	N/A
6/30/2016	17,618	2,870	N/A	1,346	N/A
3/31/2016	16,910	1,574	N/A	978	N/A
12/31/2015	16,560	1,565	N/A	2,105	N/A
9/30/2015	16,531	1,775	N/A	1,793	N/A
6/30/2015	16,383	1,790	N/A	2,172	N/A
3/31/2015	16,109	2,253	N/A	3,157	N/A
12/31/2014	15,879	2,004	N/A	3,148	N/A
9/30/2014	16,062	2,717	N/A	3,986	N/A
6/30/2014	16,206	2,688	N/A	4,136	N/A
3/31/2014	16,365	2,891	N/A	4,590	N/A
12/31/2013	16,385	2,563	N/A	3,545	N/A
9/30/2013	16,135	2,762	N/A	2,971	N/A
6/30/2013	15,806	1,360	N/A	6,502	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).

Earnings vs Market: BRM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BRM is expected to become profitable in the next 3 years.

Revenue vs Market: BRM's revenue is expected to decline over the next 3 years (-1.6% per year).

High Growth Revenue: BRM's revenue is forecast to decline over the next 3 years (-1.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BRM's Return on Equity is forecast to be very high in 3 years time (73.1%).

Bristol-Myers Squibb Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Recent updates

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

Fourth quarter dividend of US$0.60 announced

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Full year 2023 earnings released: EPS: US$3.88 (vs US$2.97 in FY 2022)

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Upcoming dividend of US$0.60 per share at 4.7% yield

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 Commands Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes At Ash 2023

Bristol-Myers Squibb Company Presents New Data At ASH 2023 Demonstrating Clinical Benefit Across B-Cell Malignancies with Breyanzi as A Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary

Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb Appoints Christopher Boerner as Chief Executive Officer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.94 (vs US$0.75 in 3Q 2022)

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 Checkmate -77T Trial

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Early Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types At Esmo2023

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Upcoming dividend of US$0.57 per share at 3.9% yield

Bristol-Myers Squibb Company to Report Q3, 2023 Results on Oct 26, 2023

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on November 1, 2023

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bristol Myers Squibb Announces New Long-Term Follow-Up Results from Two Phase 3 Studies Evaluating CAMZYOS (Mavacamten)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies